トップページ  >  ゼブラフィッシュ　Zebrafish  >  詳細

ゼブラフィッシュ　Zebrafish

AI-Driven Precision Patient-Derived Cancer Xenograft Zebrafish System Protocol

                     

2025/10/07

Since 2024, the clinical implementation of Patient-Derived Xenograft Zebrafish systems (PDXZ) has accelerated. For example, a validation study involving 55 colorectal cancer patients demonstrated that the PDXZ system predicted patient treatment response with 91% accuracy (Nature Communications 2024 Jun 5;15:4771). Furthermore, the XenoZ clinical trial (NCT03668418), led by Portugal's Champalimaud Foundation, is the world's first randomized trial involving 120 pancreatic and gastrointestinal cancer patients, with patient enrollment beginning in January 2025. Therefore, anticipating rapid progress toward future clinical implementation, we attempted to maximize accuracy by minimizing non-clinical variability factors in this PDXZ protocol, focusing on the following three points for personalized medical decision-making and drug discovery screening decisions: We report the development of: 1) a fully individualized system to support the complete automation of PDXZ expected globally by 2030, 2) AI-based quality control for zebrafish hosts, and 3) AI-based quality control for patient tumor transplantation.

関連リンク

Zebrafish & Medaka - Based Drug Discovery Society 2025 (ZMDD2025)

三重大学メディカルゼブラフィッシュ研究センター

関連ファイル

AI-Driven Precision Patient-Derived Cancer Xenograft Zebrafish System Protocol

AI-Driven Image Analysis for Precision Screening Transposon-Mediated Transgenesis of NFκB eGFP Reporter System in Zebrafish